De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

BACKGROUND: Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). MATERIALS AND METHODS: The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a fully enrolled (2012–2016), observational, prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripathy, Debu, Brufsky, Adam, Cobleigh, Melody, Jahanzeb, Mohammad, Kaufman, Peter A., Mason, Ginny, O'Shaughnessy, Joyce, Rugo, Hope S., Swain, Sandra M., Yardley, Denise A., Chu, Laura, Li, Haocheng, Antao, Vincent, Hurvitz, Sara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011632/
https://www.ncbi.nlm.nih.gov/pubmed/32043771
http://dx.doi.org/10.1634/theoncologist.2019-0446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011632/
https://www.ncbi.nlm.nih.gov/pubmed/32043771
http://dx.doi.org/10.1634/theoncologist.2019-0446

Ejemplares similares